Robert Meehan

Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study

Jeffrey S. Weber, Matteo S. Carlino, Adnan Khattak et al. · The Lancet · 2024 · 739 citations

Life Sciences, Immunology, Oncology +14

Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis)

Shivaani Kummar, Geraldine O’Sullivan Coyne, T. Khanh et al. · Journal of Clinical Oncology · 2017 · 188 citations · Full text

Medicine, Oncology, Pharmacology +13

A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectable solid tumors.

Howard A. Burris, Manish R. Patel, Daniel C. Cho et al. · Journal of Clinical Oncology · 2019 · 144 citations

Life Sciences, Immunology, Oncology +17

T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study

Justin F. Gainor, Manish R. Patel, Jeffrey S. Weber et al. · Cancer Discovery · 2024 · 100 citations

Medicine, Immunology, Oncology +17

A phase I study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36γ, for intratumoral (iTu) injection alone and in combination with durvalumab.

Manish R. Patel, Todd M. Bauer, Antonio Jimeno et al. · Journal of Clinical Oncology · 2020 · 69 citations

Medicine, Oncology, Pharmacology +16